The FDA proposed excluding active ingredients in popular obesity and diabetes drugs from compounding lists due to a lack of clinical need, impacting how large quantities of these medications can be produced. This move benefits drug manufacturers like Novo Nordisk and Eli Lilly but limits consumer access through compound pharmacies. The decision marks a significant shift in regulatory oversight over compounded medications.
Read the full article at STAT News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

![[AINews] The Unreasonable Effectiveness of Closing the Loop](/_next/image?url=https%3A%2F%2Fmedia.nemati.ai%2Fmedia%2Fblog%2Fimages%2Farticles%2F600e22851bc7453b.webp&w=3840&q=75)



